Login / Signup
Correspondence on 'Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial'.
Markus Bredemeier
Published in:
Annals of the rheumatic diseases (2020)
Keyphrases
</>
interstitial lung disease
systemic sclerosis
open label
phase iii
phase ii
study protocol
electronic health record
clinical trial
idiopathic pulmonary fibrosis
big data
rheumatoid arthritis
double blind
placebo controlled
machine learning
deep learning
artificial intelligence